Last reviewed · How we verify
NCT07419724
Construction of a Portal Hypertension Biobank
trial testing Endoscopic treatment in Variceal Bleeding in 1,000 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 16 October 2025 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2031 |
| Sites | 1 location across China |
Drugs / interventions tested
- Endoscopic treatment
Conditions studied
- Variceal Bleeding — all drugs for Variceal Bleeding →
- Portal Hypertension — all drugs for Portal Hypertension →
Sponsor
Shanghai Zhongshan Hospital
Who can join
18 and older, any sex, with Variceal Bleeding or Portal Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Esophageal and gastric variceal bleeding (EGVB) is a severe complication of portal hypertension (PH), characterized by high bleeding volume, high rebleeding rate, and high mortality. In recent years, endoscopic treatment has significantly improved therapeutic efficacy and patient survival. However, due to substantial individual variations among patients, individualized stratified management is crucial. For special populations with cirrhotic portal hypertension, clear management guidelines and clinical research evidence are lacking. The incidence of non-cirrhotic portal hypertension is increasing year by year; it has complex etiologies, lacks specific symptoms and imaging features, and poses diagnostic challenges. Currently, multi-omics research on portal hypertension is insufficient. The integration of multi-omics technologies, including genomics, radiomics, metabolomics, and gut microbiota, holds promise for a more comprehensive understanding of the pathogenesis. With continuous improvements in multi-modal medical data fusion technology, there is an urgent need to develop clinical decision support systems by combining standardized multi-omics databases with artificial intelligence techniques, thereby enhancing clinical decision-making capabilities and prognostic assessment. This study aims to expand the established portal hypertension biobank by extending the temporal depth of clinical cohort data and diversifying sample types.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07419724
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Endoscopic treatment
Trials testing the same drug.
- NCT06863519 — Evaluation of Endoscopic Treatment Effect Based on HVPG · enrolling by invitation
- NCT06635122 — TIPS for Platinum-Related Porto-Sinusoidal Vascular Disease With Variceal Bleeding · active not recruiting
- NCT05141617 — Management of Oxaliplatin-related Gastroesophageal Variceal Bleeding · NA · unknown
Other recruiting trials for Variceal Bleeding
Currently open trials in the same condition.
- NCT06881628 — Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients · Phase 4 · recruiting
- NCT06669806 — Effectiveness and Safety of TIPS Stent Graft in the Treatment of Cirrhosis and Complications of Portal Hypertension · NA · recruiting
- NCT06624098 — Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma · NA · recruiting
- NCT05629845 — Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients · NA · recruiting
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07419724 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 19 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07419724.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing